(Q38564746)

4 September 2017

1 reference

title

The wasting continuum in heart failure: from sarcopenia to cachexia (English)

1 reference

4 September 2017

1 reference

1

Stephan von Haehling

1 reference

4 September 2017

publication date

12 August 2015

1 reference

Proceedings of the Nutrition Society

4 September 2017

published in

1 reference

4 September 2017

volume

74

1 reference

4 September 2017

issue

4

1 reference

4 September 2017

page(s)

367-377

1 reference

Skeletal Muscle Function and Its Relation to Exercise Tolerance in Chronic Heart Failure

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Skeletal muscle apoptosis in experimental heart failure: the only link between inflammation and skeletal muscle wastage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

The "muscle hypothesis" of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Resting energy expenditure and the effects of muscle wasting in patients with chronic heart failure: results from the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Metabolism and the heart: an overview of muscle, fat, and bone metabolism in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Cachexia: a therapeutic approach beyond cytokine antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Effects of aging and caloric restriction on mitochondrial energy production in gastrocnemius muscle and heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Apoptosis and aging: role of the mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Mitochondrial free radical generation, oxidative stress, and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Alterations in muscle attenuation following detraining and retraining in resistance-trained older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Thigh composition in young and elderly men determined by computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Physiological changes in ageing muscles

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Relationship between muscle fibre composition, glucose transporter protein 4 and exercise training: possible consequences in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Fuel selection, muscle fibre

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Strength, mobility and falling in women referred to a geriatric outpatient clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Low appendicular skeletal muscle mass (ASM) with limited mobility and poor health outcomes in middle-aged African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Testosterone and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Sarcopenia with limited mobility: an international consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Cachexia: a new definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal c

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

The role of apoptosis in age-related skeletal muscle atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Cachexia: a problem of energetic inefficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Cancer cachexia: impact, mechanisms and emerging treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Patients' rationale for declining participation in a cancer-associated weight loss study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Formoterol in the treatment of experimental cancer cachexia: effects on heart function

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Psychosocial impact of cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Cachexia as a major public health problem: frequent, costly, and deadly

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Molecular mechanisms and treatment targets of muscle wasting and cachexia in heart failure: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Myopenia-a new universal term for muscle wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Frailty and the aging male.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Invited review: Aging and sarcopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Epidemiology and consequences of sarcopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Muscle wasting disease: a proposal for a new disease classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

A framework for prescription in exercise-oncology research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Muscle wasting in heart failure: An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Cancer cachexia prevention via physical exercise: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Development and relative validity of a new field instrument for detection of geriatric cachexia: preliminary analysis in hip fracture patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

The effect of physical training on systemic proinflammatory cytokine expression in heart failure patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Development of a practical screening tool to predict low muscle mass using NHANES 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Toward a sex-specific relationship between muscle strength and appendicular lean body mass index?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Sarcopenia: characteristics, mechanisms and functional significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Minireview: Adiposity, Inflammation, and Atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Increased catabolic activity in adipose tissue of patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Cardiac cachexia: a systematic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Inflammatory mediators in chronic heart failure: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Growth hormone resistance in chronic heart failure and its therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Chronic heart failure reduces Akt phosphorylation in human skeletal muscle: relationship to muscle size and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Sarcopenia: describing rather than defining a condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

An overview of sarcopenia: facts and numbers on prevalence and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Cardiac cachexia in early literature: a review of research prior to Medline

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Wasting as independent risk factor for mortality in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Sarcopenia: origins and clinical relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

From sarcopenia to frailty: a road less traveled

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Body composition and prognosis in chronic systolic heart failure: the obesity paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

Prolonged electrical muscle stimulation exercise improves strength, peak VO2, and exercise capacity in patients with stable chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Abnormalities of skeletal muscle in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Exercise training prevents oxidative stress and ubiquitin-proteasome system overactivity and reverse skeletal muscle atrophy in heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Alterations of skeletal muscle in chronic heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Standardization of nomenclature of body composition in weight loss

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: A prospective study

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Mechanisms of Cachexia in Chronic Disease States

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Effect of atrial natriuretic peptide on adiponectin in patients with heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Plasma cytokine parameters and mortality in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

Age changes in body composition revealed by computed tomography

1 reference

https://api.crossref.org/works/10.1017%2FS0029665115002438

7 January 2021

10.1017/S0029665115002438

Identifiers

DOI

1 reference

4 September 2017

1 reference